Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.39 - $3.75
Previous CloseN/A
Volume228.85K
Average Volume (3M)2.97M
Market Cap
$29.55M
Enterprise Value$34.18M
Total Cash (Recent Filing)$15.85M
Total Debt (Recent Filing)$19.75M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 07, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding43,591,230
10 Day Avg. Volume8,310,762
30 Day Avg. Volume2,966,902
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.74
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit67.43
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$7.00Price Target Upside1490.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Rani Therapeutics Holdings News
PremiumCompany Announcements
Rani Therapeutics Announces New Securities Purchase Agreement
PremiumCompany Announcements
Rani Therapeutics Faces Nasdaq Non-Compliance Notice
PremiumCompany Announcements
Rani Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
Rani Therapeutics Secures $4.3M via Series D WarrantBulls Say, Bears Say
Bulls Say
Market PotentialThe obesity market is massive, with ~70M obese American adults, creating potential for multiple players and the versatility of RaniPill could enable further partnerships or internal development programs as obesity drugs come off-patent.
Product DevelopmentRani has demonstrated successful delivery of semaglutide via RaniPill with comparable bioavailability, weight loss, and PK, which could lead to a nearer term path to revenue in markets where semaglutide is coming off patent.
Strategic PartnershipsRani entered into a research agreement with Chugai Pharmaceutical Co., indicating a significant collaboration.
Bears Say
Financial PerformanceRani Therapeutics reported 1Q25 results with a net loss of ($12.7M) and ended the period with $15.9M in cash, indicating the company will require additional capital in the near term.
Funding RequirementsRani expects its cash runway to last into 3Q25 without additional funding.
Risk FactorsRisks include, but are not limited to: negative Phase 2 data; negative clinical readouts with other candidates; failure to achieve approvals for key pipeline projects; possible partnership risk; slower-than-projected market uptake.
Options Prices
Currently, No data available
---
Ownership Overview
24.83% Insiders
2.53% Mutual Funds
0.13% Other Institutional Investors
70.39% Public Companies and
Individual Investors
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $0.39 and its highest was $3.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Rani Therapeutics Holdings’s market cap is $29.55M.
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is Aug 07, 2025 which is in 14 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on May 13, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.22.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -0.29.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 43,591,230 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.667%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
Rani Therapeutics Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (1490.91% Upside)
$7.00 (1490.91% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.06%
12-Months-Change
Fundamentals
Return on Equity
-1372.59%
Trailing 12-Months
Asset Growth
-54.92%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings (RANI) is a healthcare company focused on developing innovative oral biologics utilizing its proprietary RaniPill technology. The company operates within the biotechnology and pharmaceutical sectors, offering a unique solution for the oral delivery of biologics, which are traditionally administered via injection. Rani's core product, the RaniPill capsule, is designed to deliver large-molecule drugs through the gastrointestinal tract, thereby improving patient compliance and expanding the potential market for biologic therapies.
RANI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.Read More>RANI Stock 12 Month Forecast
Average Price Target
$7.00
▲(1490.91%Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Adverum Biotechnologies
―
IGM Biosciences
―
Adagene
―
TScan Therapeutics
―